Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,703.0 02/08/16
52 week low1,573.0 19/05/17
52 week change -534.0 (-23.99%)
4 week volume22,197,446 01/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut it...

Broker Forecast - Cantor Fitzgerald issues a broker note on Hikma Pharmaceuticals PLC

Cantor Fitzgerald today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price ...

Broker Forecast - Numis issues a broker note on Hikma Pharmaceuticals PLC

Numis today reaffirms its add investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and set its price target at 20...

Miners rally on stronger commodity prices

Miners and utilities kept the FTSE in positive territory on a quiet day for corporate news. Anglo American (AAL) and Rio...

Result of AGM

RNS Number: 7108F Hikma Pharmaceuticals Plc 19 May 2017 Hikma Pharmaceuticals PLC Voting Results of 2017 Annual General Meeting LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the " Company ") announces its Annual General Meeting (" AGM "), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am...

Why this pharma giant slumped to a three-year low

This share is in freefall after delays to the approval process for one of its drugs. However, David Brenchley finds that anal...

Oil prices climb on potential output cuts

The FTSE gained momentum thanks to a rise in oil prices on hopes that output cuts would continue. Brent crude oil rallied...

FTSE makes positive start as sterling vaults higher

The FTSE embarked on a positive note as did its European counterparts, despite sterling vaulting higher on the dollar in w...

Fundamental DataMore

P/E ratio25.444
EPS66.5
Dividend yield1.95 %

Latest discussion posts More

  • AGM tomorrow

    May elaborate on the reasons for FDA rejection despite HIk being very confident of approval & revenue flows from the second half of this year.
    18-May-2017
    dave297
  • Ouch

    Looks like a basic schoolboy error. Or do the FDA have another ax to grind? Does not inspire confidence, they should have got this sorted out.
    12-May-2017
    Ravinell
  • Ouch

    Nasty reaction to the FDA news; but I think it's overdone. Basically it means Hikma won't be earning any money from a product in a market where it has never earned any money. ...
    11-May-2017
    Hardboy

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.31%
GLAXOSMITHKLINE27%
RDS 'B'25%
BP24%
VODAFONE GRP.24%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK